QQ客服 官方微博 反馈留言

	高表达CD123的CD34~+CD19~+细胞为Ph染色体阳性急性淋巴细胞白血病复发预测的新标记
	孔圆 ; 黄晓军 ; 郝乐 ; 秦亚溱 ; 江倩 ; 江浩 ; 刘艳荣 ; KONG Yuan ; HUANG Xiao-Jun ; HAO Le ; QIN Ya-Zhen ; JIANG Qian ; JIANG Hao ; LIU Yan-Rong
	2016-03-30 ; 2016-03-30
关键词	CD123 CD34+CD19+细胞 急性淋巴细胞白血病 Ph染色体 CD123 CD34+CD19+cell acute lymphoblastic leukemia Ph chromosome R733.71
其他题名	CD34~+ CD19~+ Cells with CD123 Overexpression Are A Novel Prognostic Marker in Ph Chromosome-positive Acute Lymphoblastic Leukemia
中文摘要	本研究探讨CD123在成人Ph染色体阳性急性淋巴细胞白血病(Ph chromosome-positive acute lymphoblastic leukemia,Ph+ALL)患者CD34+CD19+细胞上的表达特点及其在复发预测中的作用。2010年1月-2012年4月北京大学血液病研究所经规范化诊治的49例18-60岁初诊Ph+ALL患者纳入本研究,在初诊及治疗后不同时间点通过多色流式细胞术监测CD34+CD19+细胞上CD123的荧光强度及表达比例,同时利用实时定量聚合酶链式反应(real-time quantitative polymerase chain reaction,RQ-PCR)监测BCR-ABL1融合基因变化。与正常B祖细胞相比,获得完全缓解后任意时间点骨髓标本中异常高表达CD123的CD34+CD19+细胞大于10个定义为免疫残留阳性(FCM阳性)。结果表明,①初诊及复发Ph+ALL患者CD34+CD19+细胞上CD123的平均荧光强度(mean fluoresce intensity,MFI)〔8.52(3.71-32.35)vs 8.93(4.79-29.74)vs 1.31(0.21-1.75),P<0.05〕,以及异常高表达CD123的CD34+CD19+细胞比例〔84.63%(55.07%-99.96%)vs 84.50%(57.68%-99.80%)vs 0.99%(0.45%-1.83%),P<0.05〕均显著高于健康供者的正常B祖细胞。入组的全部初诊及复发Ph+ALL患者的CD34+CD19+细胞均高表达CD123。②多色流式细胞术监测异常高表达CD123的CD34+CD19+细胞和RQ-PCR检测BCR-ABL1融合基因的结果之间具有良好的相关性(n=49例,360对,Spearman r=0.90,P<0.0001)。③13例复发患者中有11例在复发前3个月MRD监测表明,在复发前中位时间60(30-73)天均检出FCM阳性。结论:通过多色流式细胞术检测异常高表达CD123的CD34+CD19+细胞可与RQ-PCR检测BCR-ABL1融合基因互为补充,共同应用于Ph+ALL患者的MRD监测以及复发预测。; This study was aimed to investigate the characteristics of CD123 expression on CD34+CD19+cells and its prognostic significance as a novel MRD biomarker in Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph+ALL) patients.Consecutive newly diagnosed Ph+ALL patients(n = 49) in Peking University Institute of Hematology from January 2010 to April 2012 were prospectively enrolled in this study.At diagnosis and different time points during treatment,CD123 expression on CD34+CD19+cells was examined by multiparameter flow cytometry(MFC).More than 10 CD34+CD19+cells with CD123 overexpression in bone marrow samples after complete remission were defined as FCM positive(FCM+).The BCR-ABL1 transcript was detected by real-time quantitative polymerase chain reaction(RQ-PCR) concurrently.The results showed that mean fluorescence intensity of CD123 on CD34+CD19+cells in newly diagnosed Ph+ALL and relapsed Ph+ALL patients was significantly higher than that of normal B-cell progenitors〔8.52(3.71-32.35) vs 8.93(4.79- 29.74) vs 1.31(0.21- 1.75),P < 0.05〕.In addition,ratio of the CD34+CD19+cells with CD123 overexpression in newly diagnosed Ph+ALL and relapsed Ph+ALL patients were significantly higher than that of normal B-cell progenitors〔84.63%(55.07%- 99.96%) vs 84.50%(57.68%- 99.80%) vs0.99%(0.45%- 1.83%),P < 0.05〕.CD34+CD19+cells with CD123 overexpression were detected in all newly diagnosed and relapsed Ph+ALL patients.A good correlation was found between the MRD results of CD34+CD19+cells with CD123 overexpression detected by MFC and that detected by RQ-PCR(n = 360 pairs,Spearman r = 0.90,P <0.0001).Among 13 cases relapsed during follow up,11 cases of them were detected by FCM+at a median time of 60(30-73) days before the recurrence.It is concluded that as a complementary to RQ-PCR,detection of the CD34+CD19+cells with CD123 overexpression by MFC promises to be an efficient tool for MRD assessment and risk stratification in human Ph+ALL.
语种	中文 ; 中文
内容类型	期刊论文
源URL	[http://ir.lib.tsinghua.edu.cn/ir/item.do?handle=123456789/148423]
专题	清华大学
推荐引用方式 GB/T 7714	孔圆,黄晓军,郝乐,等. 高表达CD123的CD34~+CD19~+细胞为Ph染色体阳性急性淋巴细胞白血病复发预测的新标记[J],2016, 2016.
APA	孔圆.,黄晓军.,郝乐.,秦亚溱.,江倩.,...&LIU Yan-Rong.(2016).高表达CD123的CD34~+CD19~+细胞为Ph染色体阳性急性淋巴细胞白血病复发预测的新标记..
MLA	孔圆,et al."高表达CD123的CD34~+CD19~+细胞为Ph染色体阳性急性淋巴细胞白血病复发预测的新标记".(2016).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。